Introduction
The N-methyl-D-aspartate (NMDA) subtype of excitatory amino acid receptors is a ligand-gated ion channel that contains discrete but interdependent functional domains, each with separate ligand binding sites (recently reviewed in McBain & Mayer, 1994) . Among others there is a transmitter recognition site for acidic amino acids such as L-glutamate; a cation channel with a unique voltage-dependent regulation by magnesium; a polyamine site; and a recognition site for neutral animo acids such as glycine. The binding of glycine to its recognition site on the NMDA receptor is strychnine-insensitive and was initially shown to augment the electrophysiological actions of NMDA in cultured neurones (Johnson & Ascher, 1987) . Subsequent studies in both Xenopus oocytes expressing NMDA-gated cation channels (Kleckner & Dingledine, 1988; Lerma et al., 1990) and primary cultures of the rat visual cortex (Huettner, 1989) have demonstrated that occupation of the glycine site by an agonist is an absolute requirement for NMDA receptor activation and that glycine acts as a coagonist at this receptor (Kleckner & Dingledine, 1988) .
1-Aminocyclopropanecarboxylic acid (ACPC) is a specific high affinity ligand (Ki -32 nM) at strychnine-insensitive glycine sites ) that has been reported to exhibit partial agonist activity in both neurochemical and electrophysiological (Watson & Lanthorn, 1990; Priestley & Kemp, 1994) studies. It has been hypothesized that if the glycine co-agonist site needs to be occupied for the activation of the NMDA receptor complex and this is also an absolute requirement in vivo, then a partial agonist such as ACPC could function as an NMDA antagonist in vivo Trullas et al., 1989) . In agreement with this hypothesis, and similarly to both competitive NMDA antagonists and use-dependent channel blockers, ACPC exhibited anticonvulsant , neuroprotective (Von Lubitz et al., 1992) , 1 Author for correspondence.
anxiolytic (Trullas et al., 1989) , and antidepressant (Trullas & Skolnick, 1990) actions in animal models. To investigate the mechanisms involved in the functional NMDA receptor antagonist properties of ACPC, the present study was designed to evaluate the effects of this compound on NMDA receptor function using an in vitro functional assay for NMDA receptors (Pittaluga & Raiteri, 1990) .
Previous investigations have shown that NMDA-sensitive receptors are present on noradrenergic axon terminals of rat cerebral cortex and hippocampus (Pittaluga & Raiteri, 1990; Fink et al., 1990 (Pittaluga & Raiteri, 1990; Gothert & Fink, 1991; Raiteri et al., 1992; Wang et al., 1992 (Pittaluga & Raieri, 1990; G6thert & Fink, 1991; Wang et al., 1992 Pharmacology (1996) 118, 901-904 was rapidly dissected on ice and homogenized with a Teflonglass Potter homogenizer in 40 volumes of 0.32 M sucrose buffered at pH 7.4 with sodium phosphate (0.01 M). Homogenates were centrifuged at 1000 g for 5 min, the pellet was discarded and the supernatant was again centrifuged at 12,000 g for 20 min. The crude synaptosomal pellet was then resuspended in a standard medium having the following composition (in mM): NaCl 125, KC1 3, MgSO4 1.2, CaCl2 1.2, NaHCO3 22, NaH2PO4 1, glucose 10, pH 7.2 to 7.4 and continuously aerated with 95% 02 and 5% CO2 at 37'C.
Neurotransmitter release
The release of [3H]-NA from synaptosomes was measured in a continuous superfusion system as described by Raiteri et al. (1974) . Briefly, after incubation of synaptosomes (15 min, 370C) in the presence of [3H]-NA (0.04 yM, 39 Ci mmol-') aliquots of the synaptosomal suspension (0.24 mg protein/ chamber) were distributed on 0.65 ym Millipore filters and placed at the bottom of a set of parallel superfusion chambers. After 20 min of superfusion the standard medium was replaced with a medium without MgSO4. Two-minute fractions were collected starting at t = 37.5 min (t = 0 being the beginning of superfusion). The amount of radioactivity released into each fraction was calculated as the percentage of the total synaptosomal tritium at the start of the fraction collected. Tritium release in each fraction was expressed as a ratio over the first fraction collected (Fx/F1). Preliminary studies indicated that the maximal effects of drugs on tritium release were reached in the third fraction (results not shown). Thus, the effects of drugs on tritium release were evaluated by calculating the ratio of percentage tritium release in fraction 3 (F3), corresponding to the maximal effect, and the tritium release in the first fraction collected (F1, in which no drugs were present). This F3/F1 ratio was compared with the corresponding F3/F1 ratio obtained for the respective control groups. NMDA, glycine and ACPC were added at the end of the first fraction. In experiments evaluating the effects of ACPC on the potentiation by glycine of NMDA-evoked tritium release, ACPC was added 10 min before NMDA and glycine. Estimates of E,,, (maximal effect) and ECm (molar concentration of drug producing 50% of its maximal effect) were calculated for glycine and ACPC from concentration-response experiments by non-linear regression analysis using the SigmaPlot computer programme (Jandel, San Rafael, CA, U.S.A.).
Statistical analysis
Results represent mean+s.e.mean. Statistical differences between groups were analyzed with Student's paired t test; P<0.05 was considered to be significant. 
Results
The spontaneous basal tritium efflux from synaptosomes prepared from rat hippocampus and pre-incubated with [3H]-NA in the first fraction collected (F1) was 1.29 + 0.04% (per 2 min) of the total remaining radioactivity. In the absence of added drugs, the ratio of % tritium efflux of the third over the first fraction (F3/F1) was 0.87+0.02. NMDA (100 gM) stimulated tritium release in the third fraction, raising the F3/F1 ratio to 1.18+0.04 which represents a 36% increase in F3/F1 ratio when compared to unstimulated basal levels. Addition of glycine (10 jM) potentiated the effects of NMDA on tritium release and significantly increased the F3/F1 ratio by 27% to 1.50+0.07 (Figure 1) . Similarly, the addition of ACPC (0.1 pM) to the superfusion medium enhanced the NMDAevoked tritium release in the third fraction and increased the F3/F1 ratio by 26% to 1.49 + 0.04. 7Kyn, an antagonist at the glycine site of the NMDA receptor, at a concentration of 10 pM significantly antagonized the effects of both glycine and ACPC. Furthermore, 7Kyn completely blocked the effect of NMDA (100 pM) in the absence of added glycine, indicating the presence of glycine either in the synaptosomal samples or in the assay buffers (Figure 1) .
Glycine produced a concentration-related increase in the NMDA-evoked overflow of tritium, with an EC50 Of 1.82+0.04 gM and an E,, of 84+11% when compared to effect of NMDA in the absence of added glycine. ACPC also potentiated the effect of NMDA but with a significantly lower EC50 (43 + 6 nM) and a significantly lower maximal effect (E,,,,= 40 +9%) when compared to glycine (Figure 2) . log Drug (M) Figure 2 Concentration-response curves for the effects of glycine (0) . Electrophysiological studies performed in several laboratories confirm this hypothesis but suggest that the estimation of the intrinsic activity of ACPC at the strychnine-insensitive glycine site may depend on the experimental assay system and the type of functional NMDA receptor activity measured. Thus, electrophysiological studies report intrinsic activity values for ACPC between 77 and 95% compared to glycine, significantly higher than the reported values in radioligand binding experiments (McBain et al., 1989; Watson & Lanthorn, 1990; Bashir et al., 1990; Priestley & Kemp, 1994) .
In the present experiments, the E,. of ACPC for potentiation of the effects of NMDA on synaptosomal [3H]-NA release was 48% of the Emzt of glycine (Figure 2) Figure 2 ) but within the range of the affinities reported in electrophysiological experiments (EC50 = 0.7 + 0.1 gM, Kleckner & Dingledine, 1988) . However, ACPC showed an almost thirty fold higher potency than glycine. These findings suggest that ACPC exhibits lower maximal effect and higher potency in presynaptic NMDA receptor assays than in assay prepara- (0) (Laurie & Seeburg, 1994) .
Glycine is thought to be present continuously in the extracellular space (McBain & Mayer, 1994 
